EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, In Silico ADMET Profiling, and Molecular Docking of a Novel Bis-dimethylamino Hydrazone as a Potent Dual Inhibitor of Monoamine Oxidases

Akram Al Busaidi, Athra Al Habsi, Aflah Al Jamoudi, Taqwa Al Moqbali, Abir Al Rumhi, Mahammad Ishaq Beludari, Gopala Krishna Devisetty

Current Trends in Biotechnology and Pharmacy · 21.07.2026 · 20 (3) · 3021-3028

DOI: 10.5530/ctbp.2026.3.25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Trends in Biotechnology and Pharmacy, online erschienen am 21.07.2026. Verfasst von Akram Al Busaidi und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoamine oxidases (MAO-A and MAO-B) play a key role in the metabolism of neurotransmitters, and their dysregulation is linked to neurological disorders. Hydrazone scaffolds are known for their versatile biological activities, including MAO inhibition. In this work, a new hydrazone derivative, 4-(Dimethylamino) benzaldehyde (4-dimethylamino) benzylidene hydrazone (DMBH-1), was synthesized through the condensation of hydrazine hydrate with para-dimethylamino benzaldehyde. The reaction produced a yellow crystalline solid with a 65% yield after recrystallization using chloroform. The molecular formula of the compound is C18H22N4, with a molecular weight of 294.39 g/mol. Structural confirmation was achieved through UV–Visible spectroscopy, FT-IR, 1H and 13C NMR, and mass spectrometry. Molecular target prediction using SwissTargetPredict indicated affinity towards human monoamine oxidases MAO-A and MAO-B. Docking studies were performed using AutoDock against MAO-A PDB structures 2Z5X and 2BXR, and MAO-B structures 1GOS, 2V5Z, and 6FW0. DMBH-1 showed strong binding energies across all targets, with scores of –8.55 kcal/mol (2Z5X) and –8.35 kcal/mol (2BXR) for MAO-A. For MAO-B, the compound showed binding energies of –8.47 (1GOS), –8.74 (2V5Z), and –9.22 kcal/ mol (6FW0). These values were superior to standard MAO-B inhibitors including safinamide (–7.18 to –8.72), rasagiline (–6.88 to –7.11), and selegiline (–6.23 to –6.94). DMBH-1 also showed stronger affinity than MAO-A inhibitors harmine (-7.13 to -7.67), moclobemide (-7.05 to -7.28), and clorgyline (6.35 to 6.60). SwissADME analysis showed favourable properties: molecular weight 294.39 g/mol, TPSA 31.20 Ų, consensus LogP 3.25, high GI absorption, BBB permeability, and no PAINS alerts. The bioavailability score was 0.55 with a synthetic accessibility of 2.38. Overall, DMBH-1 exhibits strong predicted MAO inhibitory activity and promising drug-likeness, indicating good potential as a lead molecule for CNS-related drug discovery.

Zitieren

APA

Busaidi, A. A., Habsi, A. A., Jamoudi, A. A., Moqbali, T. A., Rumhi, A. A., Beludari, M. I., & Devisetty, G. K. (2026). Design, Synthesis, In Silico ADMET Profiling, and Molecular Docking of a Novel Bis-dimethylamino Hydrazone as a Potent Dual Inhibitor of Monoamine Oxidases. Current Trends in Biotechnology and Pharmacy, 20(3), 3021-3028. https://doi.org/10.5530/ctbp.2026.3.25

Vancouver

Busaidi AA, Habsi AA, Jamoudi AA, Moqbali TA, Rumhi AA, Beludari MI, et al. Design, Synthesis, In Silico ADMET Profiling, and Molecular Docking of a Novel Bis-dimethylamino Hydrazone as a Potent Dual Inhibitor of Monoamine Oxidases. Current Trends in Biotechnology and Pharmacy. 2026;20(3):3021-3028. doi:10.5530/ctbp.2026.3.25

BibTeX
@article{Busaidi2026,
  author = {Busaidi, Akram Al and Habsi, Athra Al and Jamoudi, Aflah Al and Moqbali, Taqwa Al and Rumhi, Abir Al and Beludari, Mahammad Ishaq and Devisetty, Gopala Krishna},
  title = {Design, Synthesis, In Silico ADMET Profiling, and Molecular Docking of a Novel Bis-dimethylamino Hydrazone as a Potent Dual Inhibitor of Monoamine Oxidases},
  journal = {Current Trends in Biotechnology and Pharmacy},
  year = {2026},
  volume = {20},
  number = {3},
  pages = {3021--3028},
  doi = {10.5530/ctbp.2026.3.25}
}
Kostenlos starten →